Tags

Type your tag names separated by a space and hit enter

[Use of nanoparticles as radiosensitizing agents in radiotherapy: State of play].

Abstract

Nanomedicine has undergone significant development since the 2000s and it is only very recently that two metallic nanoparticles have emerged in clinical trials. The mechanism of these radiosensitizing agents is based on the presence of atoms with a high atomic number (Z) allowing a higher dose deposition into the tumor during irradiation. The first nanoparticle used in humans is NBTXR3, composed of hafnium (Z=79), with intratumor injection for the treatment of sarcoma. Another gadolinium-based nanoparticle (Z=64), AGuIX, has been used for intravenous injection in the treatment of brain metastases. The preliminary results are promising in terms of feasibility, safety and efficacy, as evidenced by the significant number of ongoing clinical trials. The upcoming challenges for the development of nanoparticles will be the targeting of cancer cells, their biodistribution into the body, their eventual toxicity and their industrial production. In the coming years, modalities of administration and optimal combinations with radiotherapy should be defined in connection with fundamental research.

Authors+Show Affiliations

Clinique universitaire cancérologie radiothérapie, CHU Grenoble-Alpes, BP217, 38043 Grenoble, France; Rayonnement synchrotron pour la recherche biomédicale (STROBE), Inserm UA07, université Grenoble-Alpes, 38000 Grenoble, France. Electronic address: cverry@chu-grenoble.fr.Institut des sciences moléculaires d'Orsay ISMO (UMR 8214), université Paris Saclay, université Paris Sud, CNRS, 91405 Orsay, France. Electronic address: erika.porcel@u-psud.fr.Département de radiothérapie, Gustave-Roussy cancer campus, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Inserm, U1030, 114, rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: cyrus.chargari@gustaveroussy.fr.Laboratoire de radiobiologie cellulaire et moléculaire, faculté de médecine Lyon-Sud, UMR CNRS5822/IN2P3, IPNL, PRISME, 69921 Oullins cedex, France. Electronic address: claire.lafrasse-rodriguez@univ-lyon1.fr.Clinique universitaire cancérologie radiothérapie, CHU Grenoble-Alpes, BP217, 38043 Grenoble, France; Service de radiothérapie, centre Francois-Baclesse, 14000 Caen, France. Electronic address: j.balosso@baclesse.unicancer.fr.

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

31540838

Citation

Verry, C, et al. "[Use of Nanoparticles as Radiosensitizing Agents in Radiotherapy: State of Play]." Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique, 2019.
Verry C, Porcel E, Chargari C, et al. [Use of nanoparticles as radiosensitizing agents in radiotherapy: State of play]. Cancer Radiother. 2019.
Verry, C., Porcel, E., Chargari, C., Rodriguez-Lafrasse, C., & Balosso, J. (2019). [Use of nanoparticles as radiosensitizing agents in radiotherapy: State of play]. Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique, doi:10.1016/j.canrad.2019.07.134.
Verry C, et al. [Use of Nanoparticles as Radiosensitizing Agents in Radiotherapy: State of Play]. Cancer Radiother. 2019 Sep 17; PubMed PMID: 31540838.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Use of nanoparticles as radiosensitizing agents in radiotherapy: State of play]. AU - Verry,C, AU - Porcel,E, AU - Chargari,C, AU - Rodriguez-Lafrasse,C, AU - Balosso,J, Y1 - 2019/09/17/ PY - 2019/07/25/received PY - 2019/07/30/accepted PY - 2019/9/22/entrez KW - AGuIX KW - NBTXR3 KW - Nanoparticle KW - Nanoparticule KW - Radiosensibilisant KW - Radiosensitizer JF - Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique JO - Cancer Radiother N2 - Nanomedicine has undergone significant development since the 2000s and it is only very recently that two metallic nanoparticles have emerged in clinical trials. The mechanism of these radiosensitizing agents is based on the presence of atoms with a high atomic number (Z) allowing a higher dose deposition into the tumor during irradiation. The first nanoparticle used in humans is NBTXR3, composed of hafnium (Z=79), with intratumor injection for the treatment of sarcoma. Another gadolinium-based nanoparticle (Z=64), AGuIX, has been used for intravenous injection in the treatment of brain metastases. The preliminary results are promising in terms of feasibility, safety and efficacy, as evidenced by the significant number of ongoing clinical trials. The upcoming challenges for the development of nanoparticles will be the targeting of cancer cells, their biodistribution into the body, their eventual toxicity and their industrial production. In the coming years, modalities of administration and optimal combinations with radiotherapy should be defined in connection with fundamental research. SN - 1769-6658 UR - https://www.unboundmedicine.com/medline/citation/31540838/[Use_of_nanoparticles_as_radiosensitizing_agents_in_radiotherapy:_State_of_play] L2 - https://linkinghub.elsevier.com/retrieve/pii/S1278-3218(19)30309-9 DB - PRIME DP - Unbound Medicine ER -